Senior Scientist Resume Example

Versatile Senior Scientist bringing advanced understanding of drug discovery developed over 11-year career and proven track record of successful development of cell-based analytical assay for drug development process including 6 years in microRNA gene therapy and 4 years in biologics. Excellent critical thinking, complex problem-solving and decision-making abilities with good grasp of business requirements and industry trends. Ready to apply knowledge and abilities to growth-oriented position with Neurocrine Biosciences.

Reading, Journaling, Volunteer, Golf, Yoga, Marathon, Tennis, Travel

PAPERS:
1. Huang X, Magnus J, Kaimal V, Karmali P, Li J, Walls M, Prudente R, Sung E, Sorourian M, Lee R, Davis S, Yang X, Estrella H, Lee EC, Chau BN, Pavlicek A, Zabludoff S. Lipid Nanoparticle-Mediated
Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth, Mol Cancer Ther. 2017 May;16(5):905-913
2. Sinha RK, Yang X, Fernández JA, Xu X, Mosnier LO, Griffin JH Apolipoprotein E Receptor 2 Mediates Activated Protein C–Induced Endothelial Akt Activation and Endothelial Barrier Stabilization, ATVB, 2016;36:518-524
3. Soroosh P, Wu J, Xue X, Song J, Sutton SW, Sablad M, Yu J, Nelen MI, Liu X, Castro G, Luna R, Crawford S, Banie H, Dandridge RA, Deng X, Bittner A, Kuei C, Tootoonchi M, Rozenkrants N, Herman K, Gao J, Yang X, Sachen K, Ngo K, Fung-Leung WP, Nguyen S, de Leon-Tabaldo A, Blevitt J, Zhang Y, Cummings MD, Rao T, Mani NS, Liu C, McKinnon M, Milla ME, Fourie AM, Sun S.
Oxysterols are agonist ligands of RORγt and drive Th17 cell differentiation. Proc Natl Acad Sci U S
A. 2014 Aug 19;111(33):12163-8
4. Zhang L, Shih AY, Yang X, Kuei C, Wu J, Deng X, Mani NS, Mirzadegan T, Sun S, Lovenberg TW, Liu C. Identification of structural motifs critical for epstein-barr virusinduced molecule function and homology modeling of the ligand docking site. Mol Pharmacol. 2012 Dec;82(6):1094-103
5. Liu CL, Yang X, Wu JJ, Kuei C, Mani NS, Zhang L, Yu JX, Sutton SW, Qin N, Banie H, Karlsson L, Sun SQ, Lovenberg TW. Oxysterols direct B-cell migration through EBI2, Nature. Jul 27;475(7357):519-23
6. Yang X, Banerjee Y, Fernández JA, Deguchi H, Xu X, Mosnier LO, Urbanus RT, de Groot PG, WhiteAdams TC, McCarty OJ, Griffin JH. Activated protein C ligation of ApoER2 (LRP8) causes Dab1dependent signaling in U937 cells. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):274-9.
7. Mosnier LO, Zampolli A, Kerschen EJ, Schuepbach RA, Banerjee Y, Fernández JA, Yang X, Riewald M, Weiler H, Ruggeri ZM and Griffin JH. Hyper-antithrombotic, Non-cytoprotective Glu149AlaActivated Protein C Mutant. Blood. 2009 Feb 24.
8. Mosnier LO, Yang X, Griffin JH. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activatible fibrinolysis inhibitordependent cytoprotective functions J Biol Chem. 2007 Nov 9;282(45):33022-33
9. Kerschen EJ, Fernandez JA, Cooley BC, Yang X, Sood R, Mosnier LO, Castellino FJ, Mackman N, Coughlin SR, Griffin JH & Weiler H. Endotoxemia and sepsis mortality reduction by nonanticoagulant activated protein C.. J Exp Med. 2007 Oct 1;204(10):2439-48
10. Yang X, Chang YJ, Lin SW, Walsh PN. Identification of residues Asn89, Ile90, and Val107 of the factor IXa second epidermal growth factor domain that are essential for the assembly of the factor X-activating complex on activated platelets. J Biol Chem, Nov 5, 279(45):46400-5, 2004
11. Yang X and Walsh PN. An ordered sequential mechanism for Factor IX and Factor IXa binding to platelet receptors in the assembly of the Factor X-activating complex. Biochem J, Aug 15;390(Pt 1):157-67, 2005
ABSTRACTS:
1. Yang X, Banerjee Y, Fernández JA, Deguchi H, Xu X, Mosnier LO, Urbanus RT, de Groot PG, WhiteAdams TC, McCarty OJ, Griffin JH. Activation of the PI3K-Akt Pathway by Activated Protein C Occurs Via a Novel Receptor, Apolipoprotein E Receptor 2 (ApoER2). Blood, 2008, Volume 112, issue 11, abstract number #695.
2. Mosnier LO, Yang X, Griffin JH. Preservation of Beneficial TAFI Functions by an Activated Protein
C Variant With Normal Cytoprotective Functions but Minimal Anticoagulant Activity. Abstract #268 Blood, Volume 110, issue 11, November 16, 2007
3. Mosnier LO, Fernandez JA, Zampolli A, Yang X, Ruggeri ZM, Griffin JH. In vivo antithrombotic potency of engineered activated protein C variants. Abstract #2704, Blood, Volume 110, issue 11, November 16, 2007
4. Kerschen EJ, Fernandez JA, Yang X, Weiler H, Griffin JH and Mosnier LO. Translational research to improve therapy in severe sepsis using a genetically engineered activated protein C variant. Oct 2007
5. Mosnier LO, Yang X, Griffin JH, Dissection of structural requirements for activated protein C anticoagulant versus cytoprotective activities, J Thromb and Hemost, 2007, abstract number OW092
6. Yang X, Mosnier LO, Griffin JH, Activated protein C requires residues 176-178 for normal anticoagulant, anti-apoptotic and anti-inflammatory activities, J Thromb and Hemost, 2007, abstract number OT090
7. Yang X, Griffin JH, Mosnier LO. Anti-inflammatory and anti-apoptotic activities of activated protein C are independent of anticoagulant activity. Blood, 2006,Volume 108, issue 11
8. Yang X, Chang YJ, Lin SW, Walsh PN. Identification of residues ASN 89, Ile 90 and Val 107 of the Factor IXa EGF2 domain that are essential for the assembly of the Factor X activating complex on activated platelets. Blood, 2003, Volume 102, Number 11, Abstract number 1091
9. Yang X and Walsh PN, The omega-loop within the Gla domain (G4-Q11) and the EGF2 domain (C88-C124) of factor IXa are both essential for the assembly of the FX activating complex on activated platelets. J Thromb and Hemost 2003; Volume 1, Supplement 1: Abstract number OC198
10. Yang X and Walsh PN. The omega-loop within the Gla domain and the EGF2 domain of Factor IXa are both necessary and sufficient for platelet binding and the assembly of the FX activating complex. Blood, 2003, Volume 102, Number 11, Abstract number 1083

PRESENTATIONS:
1. 12/2008 Fiftieth annual meeting of American Society of Hematology, San Francisco, CA (Oral presentation). “Activation of the PI3K-Akt Pathway by Activated Protein C Occurs Via a Novel Receptor, Apolipoprotein E Receptor 2 (ApoER2).”
2. 07/2007 XXIst Congress of the international society of thrombosis and hemostasis, Geneva, Switzerland (Oral presentation) “Activated protein C requires residues 176- 178 for normal anticoagulant, anti-apoptotic and anti-inflammatory activities.”
3. 12/2006 Forty-eighth annual meeting of American Society of Hematology, Orlando, FL (Oral Presentation). “Anti-inflammatory and anti-apoptotic activities of activated protein C are independent of anticoagulant activity.”
4. 12/2003 Forty-fifth annual meeting of American Society of Hematology, San Diego, CA (Poster Presentation #2) “Identification of residues ASN 89, Ile 90 and Val 107 of Xia Yang, Ph.D. Page 4 the Factor IXa EGF2 domain that are essential for the assembly of the Factor X activating complex on activated platelets.”
5. 07/2003 XIX Congress of the International Society on Thrombosis and Haemostasis, Birmingham, UK
(Oral Presentation). “The omega-loop within the Gla domain (G4- Q11) and the EGF2 domain (C88C124) of factor IXa are both essential for the assembly of the FX activating complex on activated platelets.”
6. 12/2003 Forty-fifth annual meeting of American Society of Hematology, San Diego, CA (Poster Presentation#1) “The omega-loop within the Gla domain and the EGF2 domain of Factor IXa are both necessary and sufficient for platelet binding and the assembly of the FX activating complex.” ·